Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 64Colorectal Neoplasms 58Rectal Neoplasms 46Stomach Neoplasms 44Neoplasm Metastasis 16Pancreatic Neoplasms 15Colonic Neoplasms 13Triple Negative Breast Neoplasms 11Neoplasms 11Esophageal Neoplasms 9Nasopharyngeal Carcinoma 8Locally Advanced Rectal Cancer 7Esophageal Squamous Cell Carcinoma 7Cholangiocarcinoma 6Biliary Tract Neoplasms 6Carcinoma, Hepatocellular 5HER2 Positive Metastatic Breast Cancer 4Colorectal Cancer Metastatic 4Adenocarcinoma 4Solid Tumor 3Recurrence 3Gallbladder Neoplasms 3Anus Neoplasms 3Advanced Breast Cancer 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Neuroendocrine Tumors 2Locally Advanced Colon Cancer 2Hyperthermia 2Head and Neck Neoplasms 2

Interventions

liposomal doxorubicin 1Vinorelbine 1Sequence Analysis, DNA 1Interviews as Topic 1Genome-Wide Association Study 1Docetaxel 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Genetic Predisposition to Disease × Capecitabine × Clear all
NCT03359694 2017-12-02

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Unknown
300 enrolled
Breast

Breast Neoplasms, Genetic Predisposition to Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡